Nonalcoholic fatty liver disease is a risk factor for glucose intolerance onset in men regardless of alanine aminotransferase status

Teruki Miyake1, Bunzo Matsuura2, Shinya Furukawa3, Osamu Yoshida1, Masashi Hirooka1, Teru Kumagi4, Toru Ishihara5, Sayaka Kanzaki1, Hironobu Nakaguchi1, Masumi Miyazaki1, Yoshiko Nakamura1, Yasunori Yamamoto1, Yohei Koizumi1, Yoshio Tokumoto1, Eiji Takeshita1, Yoshihito Ikeda1, Masanori Abe1, Kohichiro Kitai5, Yoichi Hiasa1

1Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 2Department of Lifestyle-Related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 3Health Service Center, Ehime University, Matsuyama, Ehime, Japan, 4Postgraduate Medical Education Center, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, and 5Ehime General Health Care Association, Matsuyama, Ehime, Japan

Keywords
Abnormal glucose tolerance, Fatty liver, Normal alanine aminotransferase

Correspondence
Yoichi Hiasa
Tel.: +81-89-960-5308
Fax: +81-89-960-5310
E-mail address: hiasa@m.ehime-u.ac.jp

J Diabetes Investig 2021
doi: 10.1111/jdi.13548

ABSTRACT

Introduction: Fatty liver disease (FLD) is a surrogate condition for glucose intolerance development. FLD may involve normal or abnormal liver enzyme levels. Whether FLD is a risk factor for glucose intolerance, regardless of liver enzyme levels, remains unknown. We assessed relationships between the development of impaired fasting glucose (IFG) and FLD, liver enzyme abnormalities, and alcohol consumption.

Materials and Methods: We retrospectively evaluated 8,664 participants with more than two annual health check-ups. Participants were classified according to sex, alcohol consumption, alanine aminotransferase (ALT) levels, and fatty liver status.

Results: In univariate analyses, IFG onset among men was related to normal or high ALT levels with FLD in the nonalcoholic and alcoholic groups (P-trend < 0.01). In multivariate analyses, IFG onset among nonalcoholic men was associated with normal or high ALT levels with FLD, independent of potential confounding factors (P-trend < 0.01). However, IFG onset was non-independently associated with any condition among alcoholic men. In univariate analyses, IFG onset among women was related to normal or high ALT levels with FLD in the nonalcoholic group (P-trend < 0.01) and high ALT levels with FLD in the alcoholic group (P-trend < 0.05). In multivariate analyses, IFG onset was independently associated with only normal ALT levels in nonalcoholic FLD women.

Conclusions: Among nonalcoholic men and women, FLD was a risk factor for IFG onset, including normal ALT concentrations. Care is needed for individuals with nonalcoholic FLD, regardless of liver injury, possibly helping reduce glucose intolerance risk.

INTRODUCTION

The increase in the incidence of metabolic diseases is linked to relatively recent lifestyle changes, such as poor diet and lack of exercise. Among these metabolic diseases, diabetes significantly increases the risk of serious progressive diseases such as polyneuropathy, renal failure, visual loss, cardiovascular disease, and hepatocellular carcinoma. Therefore, it is important to not only prevent the onset of diabetes but also treat patients who already have diabetes.

Several reports have described markers for prediabetes that may help guide interventions to prevent the onset of diabetes. Fatty liver disease (FLD) is one of the most efficient surrogate conditions for identifying patients with an elevated risk of developing prediabetes and diabetes. In this context, FLD is mainly categorized as nonalcoholic FLD (NAFLD) and alcoholic FLD (AFLD). NAFLD is clearly linked to the onset and presence of glucose intolerance, although an AFLD is not a clear risk factor for the development of glucose intolerance. However, some patients with FLDs have normal liver enzyme levels, while in others, the levels are abnormal, and it remains
unclear whether NAFLD or AFLD, regardless of the liver enzyme levels, is a risk factor for abnormal glucose tolerance. Therefore, we retrospectively assessed the relationships between the development of impaired fasting glucose (IFG) and FLD, liver enzyme abnormalities, and alcohol consumption.

MATERIALS AND METHODS
Participants
This retrospective study evaluated the medical records of 9,817 community-based Japanese individuals (4,793 men and 5,024 women, age: 21–78 years) who had undergone more than two annual health check-ups at the Ehime General Health Care Association between April 2003 and March 2017. The study protocol was approved by the Committee for Medical Ethics of Ehime University Hospital (approval no.: 1709007, University Hospital Medical Information Network ID: UMIN000016379) and was conducted according to the tenets of the Declaration of Helsinki and its later amendments. All participants were assigned numerical codes to protect their identity and the anonymized records were stored in a secure database. Informed consent was not required due to the study being a retrospective analysis of anonymized data.

After evaluating the laboratory data and medical background from the first check-up, 1,153 participants were excluded for the following reasons: (a) currently receiving anti-diabetic agents (n = 131), (b) baseline FPG of ≥ 6.61 mM (n = 698), (c) alcoholic status plus normal ALT levels but without FLD (n = 131), and/or (d) positivity for HBsAg (n = 131) or anti-HCV antibody (n = 98) (Figure 1). Thus, a total of 8,664 participants were considered eligible (3,964 men and 4,700 women) and categorized into five groups, with each group further categorized according to sex: normal (men: n = 2,106, women: n = 3,588), nonalcoholic normal ALT levels with FLD (men: n = 551, women: n = 280), nonalcoholic high ALT levels with FLD (men: n = 715, women: n = 235), nonalcoholic abnormal ALT levels and non-fatty liver disease (non-FLD) (men: n = 389, women: n = 538), alcoholic normal ALT levels with FLD (men: n = 71, women: n = 15), alcoholic high ALT levels with FLD (men: n = 68, women: n = 11), and alcoholic abnormal ALT levels and non-FLD (men: n = 64, women: n = 33). The average observation period was 5.61 ± 3.52 years (men: 5.42 ± 3.52 years, women: 5.78 ± 3.51 years).

Examinations
The participants underwent physical examination and routine testing to evaluate biochemical factors. Height and body weight of the participants were assessed with light gowns on, without shoes, and the results were used to calculate the body mass index (BMI). Blood pressure was measured using an automated sphygmomanometer while the participants were in the sitting position. Blood samples were acquired in the morning after a ≥ 10-h fast and were used to determine the values for fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), aspartate aminotransferase (AST), ALT, serum creatinine (Cre), uric acid (UA), total cholesterol (TC), triglycerides (TG), hepatitis B surface antigen (HBsAg), and antibodies for the hepatitis C virus (anti-HCV antibody).

Before the health check-up, public health nurses examined the questionnaires for their medical history, prescribed medications, family history of diabetes within two relatives, exercise habits (no habit or awareness of exercise vs. periodic exercise), smoking (no smoking vs. smoking ≥ 1 time/day), and average frequencies and quantities of alcohol consumption for all the participants.

Patients were diagnosed with FLD using abdominal ultrasonography by trained technicians who did not know the patients’ data. The diagnosis of FLD was made depending on two types of evidence (hepaticorenal contrast and liver brightness) and four different criteria (hepaticorenal echo contrast, liver brightness, deep attenuation, and vascular blurring)16,17.

Definitions
Baseline ALT levels were defined as “normal” (men: ≤ 30 U/L, women: ≤ 20 U/L) or “high” (men: > 30 U/L, women: > 20 U/L)18. Alcohol consumption was categorized as “nonalcoholic” (men: no drinking or < 210 g/week, women: no drinking or < 140 g/week) or “alcoholic” (men: ≥ 210 g/week, women: ≥ 140 g/week) (Table S1 for men and Table S2 for women). IFG onset within the observation period was assessed as an FPG level of ≥ 6.11 mM at each health check-up19,20. The reference group (“normal group”) was defined as nonalcoholic with a normal ALT levels and without FLD.

Statistical analysis
For all statistical analyses, we used JMP software for Windows (version 14.2; SAS Institute Japan, Tokyo, Japan). Normality assumption was tested using Kolmogorov-Smirnov-Lilliefors test, which revealed that none of the continuous variables were normally distributed. Thus, inter-group comparisons of continuous variables (i.e., age, BMI, blood pressure, and other routine data).
biochemical variables) were performed using Mann–Whitney U test and Steel-Dwass test. Chi-square test was used to evaluate categorical variables, which included sex, baseline lifestyle habits, and onset of IFG. Statistically significant differences were considered if two-tailed P-values were < 0.05.

Univariate Cox proportional hazards regression analyses using the forward likelihood ratio test were performed to assess the variables’ relationship with the onset of IFG. Multivariate Cox proportional hazards regression analyses were performed to calculate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for developing IFG. The multivariate model was adjusted for the following baseline metabolic disease-related factors: age, sex, BMI, systolic blood pressure (SBP), FPG, TC, TG, UA, Cre, exercise and snacking habits, and family history of diabetes21–25. The trend of association was assessed using a logistic regression model that assigned consecutive integers to the categories of the exposure variables. Spearman’s correlation coefficients were used to evaluate the relationship between the ALT level at baseline and the ALT level at endpoint in participants with the onset of IFG.

**RESULTS**

**Characteristics at baseline**

Tables 1–4 and Tables S3 and S4 show the participants’ baseline characteristics according to the category of group.

Complete data were available for the vast majority of patients, although data were missing regarding the BMI (one subject), exercise habits (two participants), and snacking habits (two participants).

Among nonalcoholic men, and relative to the normal group, the groups that had normal ALT levels with FLD, especially high ALT levels with FLD, and abnormal ALT levels without FLD had significantly higher values for many metabolic markers such as BMI, SBP, DBP, FPG, HbA1c, AST, UA, TC, TG, and IFG onset rate (Table 1 and Table S3). Relative to the normal group, lower exercise rates were observed in the groups that had normal ALT levels with FLD, and high ALT levels with FLD, and abnormal ALT levels without FLD (Table 1 and Table S3). Furthermore, relative to the normal group, high rates of snacking were observed in the groups that had normal ALT levels with FLD and high ALT levels with FLD (Table 1). The metabolic markers were similar between the alcoholic and nonalcoholic groups of men (Table 2 and Table S4).

Among nonalcoholic women, and relative to the normal group, many metabolic markers had higher values in the groups that had normal ALT levels with FLD, especially high ALT levels with FLD, and abnormal ALT levels without FLD (Table 3 and Table S5). Higher exercise rates were observed in the normal group, relative to the groups with normal ALT levels with FLD, high ALT levels with FLD, or abnormal ALT levels without FLD

---

**Table 1 | Baseline characteristics of nonalcoholic men**

|                  | Normal (n = 2,106) | Normal ALT levels and fatty liver disease (n = 551) | High ALT levels and fatty liver disease (n = 715) | P      |
|------------------|--------------------|---------------------------------------------------|-------------------------------------------------|--------|
| Age, years       | 42 (35–50)         | 45 (38–51)                                        | 42 (36–47)                                      | <0.01<bc |
| BMI, kg/m²       | 22.2 (20.7–23.8)   | 24.8 (23.2–26.5)                                  | 26.2 (24.3–28.3)                                | <0.01abc |
| SBP, mmHg        | 113 (104–123)      | 119 (109–131)                                     | 121 (112–134)                                   | 0.05abc |
| DBP, mmHg        | 71 (64–79)         | 75 (67–84)                                        | 76 (69–85)                                      | <0.01abc |
| FPG, mM          | 5.16 (4.94–5.44)   | 5.33 (5.05–5.55)                                  | 5.33 (5.05–5.55)                                | <0.01abc |
| HbA1c, %         | 54 (51–56)         | 5.5 (5.3–5.7)                                     | 5.6 (5.4–5.8)                                   | <0.01abc |
| AST, IU/L        | 20 (17–22)         | 20 (18–22)                                        | 28 (25–35)                                      | <0.01abc |
| ALT, IU/L        | 18 (15–23)         | 22 (18–26)                                        | 45 (36–60)                                      | <0.01abc |
| Cre, µM          | 796 (707–831)      | 796 (707–884)                                     | 796 (707–866)                                   | <0.01abc |
| UA, µM           | 350.9 (315.2–398.5)| 380.7 (333.1–422.3)                               | 398.5 (356.4–446.1)                            | <0.01abc |
| TC, mM           | 5.07 (4.53–5.64)   | 5.35 (4.81–5.95)                                  | 5.4 (4.89–5.95)                                 | <0.01abc |
| TG, mM           | 1.02 (0.76–1.39)   | 1.48 (1.03–2.1)                                   | 1.76 (1.24–2.46)                                | <0.01abc |
| Periodic exercise*, n | 841 (39.9%)     | 172 (31.3%)                                       | 190 (26.6%)                                     | <0.01  |
| Snacking habits**, n | 959 (45.6%)       | 287 (52.1%)                                       | 380 (53.2%)                                     | <0.01  |
| Family history of diabetes, n | 321 (15.2%) | 91 (16.5%)                                        | 120 (16.8%)                                     | 0.542  |
| Onset of impaired fasting glucose***, n | 138 (6.6%) | 83 (15.1%)                                        | 137 (19.2%)                                     | <0.01  |

Data are presented as the median (interquartile range) or number (percentage). *Exercise habit: no habit or awareness of exercise vs. periodic exercise. **Snacking habit: no snacking vs. snacking ≥ 1 time/day. ***Onset of impaired fasting glucose: ≥ 6.11 mM during the observation period. The Steel-Dwass test was used to analyze continuous variables, and the χ² test was used to analyze categorical variables. Differences were considered significant at P < 0.05. ***(Normal vs. Normal ALT levels and fatty liver disease; *Normal vs. High ALT levels and fatty liver disease; **Normal ALT levels and fatty liver disease vs. High ALT levels and fatty liver disease). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; Cre, creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides.
Data are presented as the median (interquartile range) or number (percentage). *Exercise habit: no habit or awareness of exercise vs. periodic exercise. **Snacking habit: no snacking vs. snacking ≥ 1 time/day. ***Onset of impaired fasting glucose ≥ 11 mM during the observation period. The Steel-Dwass test was used to analyze continuous variables, and the χ² test was used to analyze categorical variables. Differences were considered significant at P < 0.05 (†Normal vs. Normal ALT levels and fatty liver disease; ‡Normal vs. High ALT levels and fatty liver disease; §Normal ALT levels and fatty liver disease vs. High ALT levels and fatty liver disease). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; Cre, creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides.

(Table 3 and Table S5). Family history of diabetes was more common in the group with high ALT levels with FLD, relative to the normal group and the group with normal ALT levels with FLD (Table 3 and Table S5). Among alcoholic women, and relative to the normal group, many metabolic markers except the IFG onset rate had higher values in the groups that had normal ALT levels with FLD, high ALT levels with FLD, and abnormal ALT levels without FLD (Table 4 and Table S6). IFG onset rate had higher values in the group that had abnormal ALT levels without FLD than the normal group (Table S6). The rate of a snacking habit was higher in the normal group than in the other three groups (Table 4 and Table S6).

**Risk of IFG onset in relation to FLD and ALT levels**

The univariate analyses of men (Table 5) revealed that, relative to the normal group, there were significantly increased risks of IFG onset in the groups that had nonalcoholic normal ALT levels with FLD [hazard ratio (HR): 2.54, 95% CI: 1.93–3.33] and nonalcoholic high ALT levels with FLD (HR: 3.23, 95% CI: 2.54–4.08) (P-trend < 0.01) (Table 5). Additionally, there was an increased risk in the group with high ALT levels without FLD (HR: 1.81, 95% CI: 1.29–2.54) (P < 0.01) (Table S7). Similarly, among the alcoholic groups of men, relative to the normal group, there were significantly increased risks of IFG onset in the groups that had normal ALT levels with FLD (HR: 3.14, 95% CI: 1.7–5.8) and high ALT levels with FLD (HR: 4.16, 95% CI: 2.39–7.22) (P-trend < 0.01; Table 5). However, there was no significant association in the group with high ALT levels without FLD (Table S7).

Multivariate analyses of men were adjusted for age, BMI, SBP, FPG, TG, TC, UA, Cre, exercise and snacking habits, and family history of diabetes. The results revealed that, relative to the normal group, independently increased risks of IFG onset were observed in the groups that had nonalcoholic normal ALT levels with FLD [adjusted hazard ratio (aHR): 1.54, 95% CI: 1.15–2.06] and nonalcoholic high ALT levels with FLD (aHR: 1.78, 95% CI: 1.33–2.38) (P-trend < 0.01) (Table 5). Additionally, there was an increased risk in the group with high ALT levels without FLD (aHR: 1.54, 95% CI: 1.07–2.23) (P < 0.01) (Table S7). However, among the alcoholic groups of men, none had elevated risks of IFG onset (Table 5 and Table S7).

In the normal group, nonalcoholic normal ALT levels with FLD group, and nonalcoholic high ALT levels with FLD group, the 1-year IFG onset rates were 0.88%, 2.06%, and 1.87%; the 3-year IFG onset rates were 3.2%, 7.16%, and 11.36%; the 5-year IFG onset rates were 5.83%, 13.12%, and 17.76%; and the 10-year IFG onset rates were 10.68%, 29.12%, and 30.34%, respectively. In the nonalcoholic abnormal ALT levels without FLD group, the 1-year IFG onset rate was 0.5%, the 3-year IFG onset rate was 5.7% the 5-year IFG onset rate was 8.4%, and the 10-year IFG onset rate was 21.98%.
Moreover, in men, the ALT level at baseline was correlated with the ALT level at endpoint in participants with the onset of IFG ($r = 0.633$, $P < 0.01$).

Univariate analyses of women (Table 6) revealed that, relative to the normal group, there were significantly increased odds of IFG onset in the groups that had NAFLD (normal ALT levels with FLD (HR: 4.6, 95% CI: 2.96–7.17) and nonalcoholic high ALT levels with FLD (HR: 8.26, 95% CI: 5.54–12.29) ($P$-trend < 0.01), and alcoholic high ALT levels with FLD (HR: 9.82, 95% CI: 1.36–71.19). However, among women, only the nonalcoholic normal ALT levels with FLD group had independently elevated risks of IFG onset (aHR: 1.67, 95% CI: 1.03–2.7) (Table 6 and Table S8).

In the normal group and the nonalcoholic normal ALT levels with FLD group, the 1-year IFG onset rates were 0.14% and 1.11%; the 3-year IFG onset rates were 0.56% and 3.65%; the 5-year IFG onset rates were 1.29% and 8.27%; and the 10-year IFG onset rates were 3.88% and 15.03%, respectively.

In women, the ALT level at baseline was correlated with the ALT level at endpoint in participants with the onset of IFG ($r = 0.635$, $P < 0.01$).

**DISCUSSION**

The present study revealed that an elevated risk of IFG onset was associated with nonalcoholic men who had normal or high ALT levels with FLD and had high ALT levels without FLD, and nonalcoholic women who had normal ALT levels with FLD, independent of any potential confounding factors. However, among alcoholic men and women, as well as among nonalcoholic women who had high ALT levels with and without FLD, none of the subgroups exhibited an elevated risk of IFG onset. Additionally, in men and women, the ALT level at baseline was correlated with the ALT level at endpoint in participants with the onset of IFG. These results suggest that, especially in men, FLD in nonalcoholic patients is a risk factor for developing impaired glucose tolerance, even in individuals with normal ALT levels.

Several studies have examined the relationship between the onset of glucose intolerance and FLD. Mantovanii et al. performed a meta-analysis of the association between NAFLD and the onset of diabetes based on data from 19 observational studies with 296,439 participants and a median follow-up of 5 years. The results revealed that relative to participants without NAFLD, NAFLD was associated with the onset of diabetes, and the more severe NAFLD that was identified using ultrasonography or a NAFLD fibrosis score, was related to a greater risk of developing incident diabetes. However, it remains unclear whether NAFLD patients with normal ALT levels have an increased risk of developing glucose intolerance.

The association between NAFLD and the development of IFG may be related to hepatokines, such as fetuin A, fetuin B, retinol-binding protein 4, and selenoprotein P, which are...
secreted from hepatocytes and upregulated in the state of hepatic steatosis. These proteins also induce insulin resistance by suppressing the insulin-induced tyrosine phosphorylation of the insulin receptor or inactivating adenosine monophosphate-activated protein kinase. FLD is also associated with increases in diacylglycerols and ceramides, which are mediators of lipid-influenced hepatic insulin resistance. Moreover, impaired hepatocellular insulin signaling decreases glycogen synthesis and de novo lipogenesis, while increasing gluconeogenesis. Ceramide-induced protein kinase C-ζ activation also exacerbates the translocation of AKT to the plasma membrane and prevents AKT from participating in insulin signaling. Additionally, ceramide activates protein phosphatase 2A and dephosphorylates AKT resulting in the inactivation of AKT.

Interestingly, our results indicate that alcoholic fatty liver is not a risk factor for the development of IFG, which is

Table 4 | Baseline characteristics of alcoholic women

|                          | Normal (n = 3,588) | Normal ALT levels and fatty liver disease (n = 15) | High ALT levels and fatty liver disease (n = 11) | P        |
|--------------------------|-------------------|--------------------------------------------------|-----------------------------------------------|----------|
| Age, years               | 40 (34–46)        | 44 (39–49)                                       | 47 (45–53)                                    | <0.01b   |
| BMI, kg/m²               | 204 (19–221)      | 246 (223–285)                                    | 27 (24–29.7)                                  | <0.01ab  |
| SBP, mmHg                | 104 (96–114)      | 115 (106–125)                                    | 129 (116–144)                                 | <0.05ab  |
| DBP, mmHg                | 64 (58–71)        | 73 (65–80)                                       | 84 (80–86)                                    | <0.05ab  |
| FPG, mM                  | 4.88 (4.61–5.11)  | 5.05 (4.88–5.38)                                 | 5.13 (5.16–5.55)                              | <0.05ab  |
| HbA1c, %                 | 5.4 (5.3–5.6)     | 5.6 (5.4–5.8)                                    | 5.6 (5.4–5.9)                                 | <0.05a   |
| ALT, IU/L                | 18 (16–20)        | 19 (17–21)                                       | 25 (23–29)                                    | <0.01bc  |
| ALT, IU/L                | 13 (11–16)        | 15 (11–17)                                       | 25 (22–30)                                    | <0.05bc  |
| Cre, µM                  | 53 (53–61.9)      | 53 (49.5–61.9)                                   | 53 (44.2–61.9)                                | <0.05b   |
| UA, µM                   | 249.8 (214.1–279.6) | 279.6 (261.7–350.9)                             | 327.1 (267.7–356.9)                           | <0.05ab  |
| TC, mM                   | 5.09 (4.55–5.69)  | 4.73 (4.42–5.45)                                 | 5.66 (5.4–6.18)                               | <0.05bc  |
| TG, mM                   | 0.69 (0.54–0.93)  | 1.05 (0.52–1.53)                                 | 1.47 (1.15–1.86)                              | <0.05b   |
| Periodic exercise*, n    | 952 (26.5%)       | 5 (33.3%)                                        | 2 (18.2%)                                     | 0.69     |
| Snacking habits**, n     | 3,105 (86.5%)     | 9 (60%)                                          | 6 (54.6%)                                     | <0.01    |
| Family history of diabetes, N | 758 (21.1%) | 7 (46.7%)                                        | 3 (27.3%)                                     | 0.048    |
| Onset of impaired fasting glucose***, n | 80 (22.2%) | 1 (6.7%)                                         | 1 (9.1%)                                      | 0.16     |

Data are presented as the median (interquartile range) or number (percentage). *Exercise habit: no habit or awareness of exercise vs. periodic exercise. **Snacking habit: no snacking vs. snacking ≥1 time/day. ***Onset of impaired fasting glucose: ≥6.11 mM during the observation period. The Steel-Dwass test was used to analyze continuous variables, and the χ² test was used to analyze categorical variables. Differences were considered significant at P < 0.05. (Normal vs. Normal ALT levels and fatty liver disease; Normal vs. High ALT levels and fatty liver disease; Normal ALT levels and fatty liver disease vs. High ALT levels and fatty liver disease). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; Cre, creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides.

Table 5 | Univariate and multivariate analyses of the onset of impaired fasting glucose among men

|                          | Normal | Normal ALT levels and fatty liver disease | High ALT levels and fatty liver disease | P for trend |
|--------------------------|--------|------------------------------------------|----------------------------------------|-------------|
| Nonalcoholic group       | Incident rate (%) 138/2106 (6.6%) | 83/551 (15.1%)                          | 137/715 (19.2%)                          | <0.01       |
| Crude HR* (95% CI)       | 1.00   | 2.54 (1.93–3.33)                          | 3.22 (2.54–4.08)                         | <0.01       |
| Adjusted HR* (95% CI)    | 1.00   | 1.54 (1.15–2.06)                          | 1.78 (1.33–2.38)                         | <0.01       |
| Alcoholic group          | Incident rate (%) 11/71 (15.5%) | 3.14 (1.7–5.8)                           | 4.16 (2.39–7.22)                         | <0.01       |
| Crude HR* (95% CI)       | 1.00   | 0.92 (0.48–1.76)                          | 1.08 (0.55–2.09)                         | 0.93        |
| Adjusted HR* (95% CI)    | 1.00   |                                           |                                        |             |

*Multivariate Cox proportional hazards regression analysis was adjusted for age (years), BMI (kg/m²), SBP (mmHg), FPG (mM), Cre (µM), UA (µM), TC (mM), TG (mM), exercise habits, snacking habit, and family history of diabetes. Differences were considered statistically significant for P < 0.05. HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; BMI, body mass index; SBP, systolic blood pressure; FPG, fasting plasma glucose; Cre, creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides.
supported by findings reported in previous studies. Fueki et al. evaluated 1,029 men who had undergone medical check-ups and reported that moderate alcohol intake improved insulin resistance in healthy men, regardless of obesity. Akahane et al. performed a cross-sectional study of 2,461 men who had undergone regular health check-ups and also showed that chronic alcohol intake was inversely related to insulin resistance among Japanese men, regardless of the type of alcoholic beverage consumed. Furthermore, chronic alcohol intake increases the hepatic levels of glutathione, which is known to increase the production of the hepatic insulin sensitizing substance and improve the sensitivity to insulin. Nevertheless, other studies have indicated that high alcohol intake increased the risk of type 2 diabetes and impaired β-cell function. Therefore, further studies are needed to clarify these potential relationships.

The differences we observed between men and women might be associated with sex hormones and the distribution of adipose tissue. In this context, estrogen maintains glucose homeostasis by reducing hepatic glucose production and protecting the pancreatic β-cell function/survival and insulin secretion. Furthermore, estrogen affects adipose tissue biology and is associated with the prevention of obesity and adipose tissue distribution, as men tend to accumulate visceral adipose tissue and women tend to accumulate peripheral and subcutaneous adipose tissue. Moreover, increased visceral adipose tissue exacerbates insulin sensitivity in the muscle and liver by decreasing adiponectin production and increasing proinflammatory cytokine production. The present study included only a small number of women, which may explain why nonalcoholic fatty liver and abnormal ALT levels were not associated with the development of IFG.

The strength of our study lies in the fact that it was based on the general Japanese population and that data were nearly complete (only five data points were missing). However, there were also several limitations to consider. First, we identified only 262 alcoholic individuals (203 men and 59 women), which may be the reason for the lack of significant associations between IFG onset and FLD or high ALT levels. Second, abdominal ultrasonography is a useful diagnostic modality with fairly high sensitivity and specificity for fatty liver. However, it has low sensitivity to detect fatty liver with advanced liver fibrosis such as burn-out NASH, and the actual percentage of FLD may be underestimated. Additionally, we did not have access to data regarding FLD severity, which precluded an analysis of the association between FLD severity and the onset of IFG. Third, self-reported data were used for several of the investigated factors, which may decrease the accuracy of our findings. Fourth, we could not examine the relationship between FLD and the development of diabetes mellitus because the total number of patients with diabetes onset was 74, which was not sufficient to divide them into seven groups by sex and examine the aforementioned relationship. Fifth, we only collected data from annual health check-ups, which means that the data were not truly continuous. Finally, we only considered Japanese individuals, and studies in other populations are necessary to confirm the generalizability of our results.

In conclusion, the present study revealed that FLD in nonalcoholic patients increased the risk of developing glucose intolerance, even if the ALT level was normal. Therefore, regardless of their ALT levels, nonalcoholic patients with FLD require care to prevent the onset of prediabetes and reduce the risk of the development of diabetes and cardiovascular disease.

ACKNOWLEDGMENTS
This work was supported by JSPS KAKENHI Grant Number JP19K11743 and a research grant from Ehime University. We would like to thank Editage (www.editage.com) for English language editing.

DISCLOSURE
The author declares no conflict of interest.

REFERENCES
1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053.
2. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89–94.

3. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 6: 1246–1258.

4. Shima T, Uto H, Ueki K, et al. Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. J Gastroenterol 2019; 54: 64–77.

5. Kim CH, Park JY, Lee KU, et al. Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabet Med 2008; 25: 476–481.

6. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352–356.

7. Miyake T, Hirooka M, Yoshida O, et al. Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels. J Gastroenterol 2017; 52: 237–244.

8. Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940–2944.

9. Li CH, Chou YT, Shen WC, et al. Increased risk of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7–6.4% in a Chinese population. J Diabetes Investig 2020; 11: 1336–1343.

10. Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018; 41: 372–382.

11. Fuji Y, Miida T, Wardaningsih E, et al. Regular alcohol consumption improves insulin resistance in healthy Japanese men independent of obesity. Clin Chim Acta 2007; 382: 71–76.

12. Akahane T, Namisaki T, Kaji K, et al. Chronic alcohol consumption is inversely associated with insulin resistance and fatty liver in Japanese males. Nutrients 2020; 12: 1036.

13. Carlsson S, Hammar N, Grill V, et al. Alcohol consumption and the incidence of type 2 diabetes: a 20-year follow-up of the Finnish twin cohort study. Diabetes Care 2003; 26: 2785–2790.

14. Waki K, Noda M, Sasaki S, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort. Diabet Med 2005; 22: 323–331.

15. Okamoto M, Miyake T, Kitai K, et al. Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: a longitudinal cohort study. PLoS One 2013; 13: e0195147.

16. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954–961.

17. Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J Gastroenterol 2020; 55: 731–741.

18. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 2017; 112: 18–35.

19. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. World Health Organization, Geneva, 2006.

20. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 65–85.

21. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2003; 26: 521–524.

22. Harita N, Hayashi T, Sato KK, et al. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care 2009; 32: 424–426.

23. Sakurai M, Nakamura K, Miura K, et al. Family history of diabetes, lifestyle factors, and the 7-year incident risk of type 2 diabetes mellitus in middle-aged Japanese men and women. J Diabetes Investig 2013; 4: 261–268.

24. Waki K, Noda M, Sasaki S, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med 2005; 22: 323–331.

25. Miyake T, Kumagi T, Furukawa S, et al. Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One 2014; 9: e107882.

26. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 2017; 13: 509–520.

27. Petersen MC, Shulman Gl. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci 2017; 38: 649–665.

28. Yang CM, Carlson GP. Effects of ethanol on glutathione conjugation in rat liver and lung. Biochem Pharmacol 1991; 41: 923–929.

29. Guarino MP, Afonso RA, Raimundo N, et al. Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One 2014; 9: e107882.
32. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. *Curr Atheroscler Rep* 2004; 6: 180–185.

33. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. *Gend Med* 2009; 6: 60–75.

34. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 2001; 7: 941–946.

35. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia* 2003; 46: 459–469.

36. Chawla A, Nguyen KD, Goh YPS. Macrophage-mediated inflammation in metabolic disease. *Nat Rev Immunol* 2011; 11: 738–749.

37. Hui E, Xu A, Bo Yang H, et al. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. *J Diabetes Investig* 2013; 4: 413–425.

38. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? *Eur J Gastroenterol Hepatol* 2003; 15: 539–543.

39. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. *Hepatology* 2007; 46: 582–589.

40. Perez NE, Siddiqui FA, Mutchnick MG, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease. A retrospective observational study. *J Clin Gastroenterol* 2007; 41: 624–629.

41. Tobari M, Hashimoto E, Yatsuji S, et al. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. *Int Med* 2009; 48: 739–746.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1 |** Categories based on average alcohol consumptions (Men).

**Table S2 |** Categories based on average alcohol consumptions (Women).

**Table S3 |** Baseline characteristics of nonalcoholic men with high ALT and non-fatty liver disease.

**Table S4 |** Baseline characteristics of alcoholic men with high ALT and non-fatty liver disease.

**Table S5 |** Baseline characteristics of nonalcoholic women with high ALT and non-fatty liver disease.

**Table S6 |** Baseline characteristics of alcoholic women with high ALT and non-fatty liver disease.

**Table S7 |** Univariate and multivariate analyses of the onset of impaired fasting glucose among men.

**Table S8 |** Univariate and multivariate analyses of the onset of impaired fasting glucose among women.